Alkermes plc. Research and Development in Process
Alkermes plc. (ALKS) reported Research and Development in Process of $2.72 million for the 12-month period ending 2021-12-31, per its 10-K filed 2023-02-16.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2023-02-16
- Alkermes plc. research and development in process for fiscal 2021 was $2.72M, a 720.48% increase from fiscal 2020.
- Alkermes plc. research and development in process for fiscal 2020 was $332.00K, a 96.93% decline from fiscal 2019.
- Alkermes plc. research and development in process for fiscal 2019 was $10.82M.
| Period end | Research and Development in Process 12 month | Research and Development in Process 12 month as first filed |
|---|---|---|
| 2021-12-31 | $2.72M 10-K · filed 2023-02-16 | |
| 2020-12-31 | $332.00K 10-K · filed 2023-02-16 | $84.00K 10-K · filed 2021-02-11 |
| 2019-12-31 | $10.82M 10-K · filed 2022-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |